In March, CureVac was catapulted into the public sphere, after reports emerged that President Trump had tried to buy the company and secure the COVID-19 vaccine it is currently developing exclusively for US patients. The reports were never officially confirmed but there were a series of changes at leadership level at CureVac that followed.
A week after former CEO, Daniel Menichella, had discussed the development of a COVID-19 vaccine with the US president, it was announced that he would be leaving to be replaced by the company’s founder and former CEO, Ingmar Hoerr (pictured). No reasons were given for his departure in CureVac’s press release on the matter.
Only a few days after this announcement was made, the company followed up this announcement by announcing that Hoerr would take temporary leave for medical reasons, unrelated to the novel coronavirus outbreak. He was replaced in turn by Franz-Werner Hass, who will assume the role temporarily until Hoerr’s return.
Further than this, the biotech then revealed that it had appointed a new chairman, in the shape of Jean Stéphenne, who had previously acted as deputy chairman.